Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 -- Inivata, a leader in liquid biopsy, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place on 10-15 April 2021. Data on the Company’s InVisionFirst-Lung liquid biopsy test will also be presented.
News
Cambridge 15th March 2021: Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair.
Jo has been a non-executive director on the BBT Board for over four years and has chaired the company’s Audit Committee. She follows on from Dr Andy Richards who has formally stood down from the role after many years’ service. Dr Richards remains an active supporter of the Campus.
Cambridge and London UK: 12th March 2021
Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Research Triangle Park, NC, USA and Cambridge, UK, 9 March 2021 -- Inivata, a leader in liquid biopsy, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its RaDaR™ assay.
Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimisation of fully human antibodies, have announced that they have entered into an agreement with Quell Therapeutics Limited (Quell) regarding IONTAS / FJB’s proprietary libraries and technology platforms.
AMSBIO announce a new HER2 control cell line array that was developed and is proven as an effective slide quality control for HER2 expression in breast cancer tissue samples.
This new FFPE cell pellet microarray delivers a full dynamic range of HER2, ER and PR expression, validated by the Ventana system, to give immunohistochemical data in strong concordance with the routinely processed tissue sample.sections.
In our recent post, we have produced a clear summary infographic of all the key Covid-19 vaccines in full or early use, globally. We've included peer-review references where available, including efficacies, to help you to get up to speed quickly.
https://onyva-agency.com/2021/02/26/global-covid-19-vaccine-summary-and-...
New data reveals Knowledge Intensive (KI) firms in Cambridge continue to outperform national figures
Cambridge, UK. 3 March 2021: Medium term data on the growth of the Cambridge economy, right up to the start of the 2020 Covid lockdown, shows persistently higher annual growth rates than the national economy, particularly amongst knowledge-intensive (KI) firms. This confirms Cambridge’s status as one of the largest concentrations of KI employment in Europe. However, there are also indications that start-ups and non-KI firms are finding conditions in the city less attractive.